PCM
NPTN

Palisade Capital Management’s NEOPHOTONICS CORP NPTN Stock Holding History

Palisade Capital Management’s Portfolio NPTN Stock Details NPTN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-80,000
Closed -$730K – 582
2015
Q2 		$730K Buy
+80,000
New +$606K 0.02% 443

Other funds holding NPTN

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
NC
Nokomis Capital Dallas, Texas $349M AUM 75.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Palisade Capital Management's NPTN Position: Q3 2015 in Review

Palisade Capital Management sold out of NEOPHOTONICS CORP (NPTN) in Q3 2015, closing a stake of 80,000 shares — an estimated $730K sold.

Palisade Capital Management first reported a position in NPTN in Q2 2015 and held it in 1 quarter. The position peaked at $730K in Q2 2015. 100 funds tracked by Wall St. Rank hold NPTN as of Q3 2015.

  • Palisade Capital Management reported no remaining NEOPHOTONICS CORP position as of Q3 2015 after selling out during the quarter.
  • Palisade Capital Management sold 80,000 NEOPHOTONICS CORP shares in Q3 2015, an estimated $730K.
  • Palisade Capital Management first reported a position in NEOPHOTONICS CORP in Q2 2015 and held it in 1 quarter.
  • Palisade Capital Management's NEOPHOTONICS CORP position peaked at $730K in Q2 2015.
  • 100 funds tracked by Wall St. Rank held NEOPHOTONICS CORP as of Q3 2015.

Based on Palisade Capital Management's 13F filing for Q3 2015, filed 29 Oct 2015.